α5IA (LS-193,268) is a nootropic drug invented in 2004 by a team working for Merck, Sharp and Dohme, which acts as a subtype-selective inverse agonist at the benzodiazepine binding site on the GABAA receptor. It binds to the α1, α2, α3 and α5 subtypes, but shows much higher efficacy at the α5 subtype, and acts either as a weak partial agonist or inverse agonist at the other subtypes, with its partial agonist effect at α2 likely to be responsible for the lack of anxiety produced by this drug when compared to older α5-preferring inverse agonists such as L-655,708.

CAS：215874-86-5
中文别名：3-(5-甲基异噁唑-3-基)-6-[(1-甲基-1H-1,2,3-噻唑-4-基)甲氧基][1,2,4]噻唑并[3,4-a]二氮杂萘;
英文别名：3-(5-methylisoazol-3-yl)-6-[(1-methyl-1,2,3-triazol-4-yl)methyloxy]-1,2,4-triazolo[3,4-a]phthalazine;|A5IA;3-(5-methylisoxazol-3-yl)-6-[(1-methyl-1,2,3-triazol-4-yl)methyloxy]-1,2,4-triazolo[3,4-a]phthalazine;| inverted exclamation mark5IA;
分子式：C17H14N8O2
分子量：362.345
精确质量：362.124
Psa：109.05
Logp：1.9484

储存条件：室温，干燥

海关编码：2934999090